Relative Contraindications to Kidney Biopsy
The primary relative contraindications to kidney biopsy include uncontrolled hypertension (systolic BP >180 mmHg or diastolic BP >110 mmHg), bleeding diathesis with coagulopathy (INR >1.4-1.5, platelets <50×10⁹/L, prolonged PTT), anticoagulant/antiplatelet therapy that cannot be safely paused, solitary kidney, severe obesity limiting visualization, and inability to cooperate with the procedure.
Bleeding Risk Factors
The most critical relative contraindications center on bleeding risk, as hemorrhagic complications represent the primary danger of kidney biopsy 1.
Coagulation Parameters
- INR >1.4-1.5: While liver biopsy guidelines suggest a transvenous approach for INR >1.4 2, this threshold is applicable to kidney biopsy as well
- Platelet count <50×10⁹/L: Strongly consider alternative approaches when platelets fall below this level 2
- Fibrinogen <0.6 g/L: Particularly high bleeding risk 2
- aPTT >100 seconds: Associated with particularly high bleeding risk 2
- Prolonged bleeding time and partial thromboplastin time: Identified risk factors 1
Anticoagulant and Antiplatelet Medications
P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor): Should be paused approximately 7 days prior to biopsy, as their antiplatelet effects persist 7-10 days and are difficult to reverse 2
Aspirin: Consider stopping 3 days prior to percutaneous biopsy, though this decision depends on the indication for aspirin and urgency of the biopsy 2. The haemostatic effects are more readily reversed than P2Y12 inhibitors.
Warfarin: Stop 5 days before the procedure with point-of-care testing to ensure adequate reversal 2
Direct oral anticoagulants (DOACs): Stop 2 days prior, or longer for dabigatran depending on renal function 2
Blood Pressure Control
Elevated systolic (>180 mmHg) and diastolic blood pressure (>110 mmHg) must be reduced to the normotensive range with medications before proceeding 1, 3. Uncontrolled hypertension significantly increases bleeding risk.
Patient-Specific Factors
Demographics and Comorbidities
- Female gender: Women are more likely to bleed than men 1
- Younger age: Paradoxically associated with increased bleeding risk 1
- Decreased GFR: Advanced renal insufficiency increases complication risk 1, 4
- Morbid obesity: May limit adequate radiologic visualization, though this traditional contraindication has been questioned in recent literature 5
Anatomic Considerations
- Solitary kidney: Historically considered a contraindication, but recent evidence suggests percutaneous biopsy can be performed safely in experienced hands 5, 6. However, it remains a relative contraindication requiring careful risk-benefit assessment 7
- Failure of adequate radiologic visualization: Inability to visualize the kidney adequately with ultrasound guidance 8, 6
Procedural Factors
Number of needle passes >4: Increases bleeding risk, particularly when exceeding 4 passes 1
Special Clinical Situations
Acute Kidney Injury with Coagulopathy
Patients with acute kidney injury or acute/chronic decompensated liver disease should have biopsy avoided when possible, as these conditions are characterized by consumptive coagulopathy and low fibrinogen 2. If biopsy is necessary, use a transjugular route.
History of Abnormal Bleeding
Patients with a history of abnormal procedure-related bleeding should be referred for specialist hematology assessment prior to biopsy 2
Alternative Approaches When Relative Contraindications Exist
When relative contraindications cannot be adequately corrected but tissue diagnosis is essential:
- Transjugular (transvenous) kidney biopsy: Preferred when bleeding risk cannot be mitigated 8, 6
- Laparoscopic biopsy: Alternative surgical approach 5, 8, 6
- Open surgical biopsy: When other methods are not feasible 5, 8, 6
Critical Pitfalls
Do not use FFP to correct INR ≤2.0 prior to kidney biopsy 2—this is ineffective and wastes resources.
Vitamin K depletion should be corrected before proceeding 2
Bleeding time is not significantly predictive and has substantial limitations as a screening test 4. The PFA-100 may be a more valuable screening test for identifying patients with impaired hemostasis.
Most complications (>90%) are apparent within 24 hours, but over 33% occur after 8 hours, necessitating at least 24-hour observation 8